
usd oct pm et
summari compani develop novel antibodi therapeut target varieti rare sever
diseas state includ autoimmun disord inflamm cancer
price-to-earnings oper ep
depend sale drug
make compani vulner weak sale
obsolesc major product howev
promis pipelin low level debt posit
cash flow recent year bode well
compani abil remain go concern
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
expect sale rise
driven growth combin sale
soliri ultomiri follow
combin sale growth
expect sale strensiq grow
slowdown
growth
march announc data
ultomiri demonstr patient
paroxysm nocturn hemoglobinuria
pnh effect safe switch
treatment soliri everi week
treatment ultomiri everi week
launch sale ultomiri decemb
initi aim convert pnh
patient soliri ultomiri end
late juli alreadi
convert pnh patient
key late-stag pipelin candid
therapi aim treat
wilson diseas area
new treatment year expect
complet enrol phase trial
earli posit free cash
flow low debt leverag give us confid
firm continu support
research develop commerci
think share trade
ep estim
under-valued gener
product revenu key drug soliri
like within next year face
competit brand biosimilar
howev defend franchis
expand soliri diseas indic
convert elig soliri patient
convers patient ultomiri larg
insul former soliri sale biosimilar
competit view optimist
pipelin recent indic
expans compani
demonstr expertis manag
develop market rare diseas
risk recommend target price
includ weak sale growth soliris/ultomiri
slower-than-expect convers soliri
patient ultomiri pipelin failur
competit threat unfavor regulatori
target base
multipl ep
compar three-year forward price-to-earnings
rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop novel antibodi therapeut target
varieti sever disord includ autoimmun cardiovascular diseas inflamm cancer
global leader complement inhibit first market product soliri eculizumab
first therapi approv treatment patient paroxysm nocturn hemoglobinuria pnh
soliri design inhibit specif aspect complement compon immun system
therebi treat inflamm associ chronic hematolog neurolog disord transplant
reject autoimmun disord
soliri compris alxn product revenu soliri human monoclon antibodi
complement inhibitor block cleavag compon complement cascad
prevent final stage complement activ soliri approv treatment pnh atyp
hemolyt urem syndrom ahu gener myasthenia gravi gmg europ japan
sever countri
latest commerci market drug ultomiri formerli approv decemb
fda treatment patient pnh announc top-lin phase
switch data ultomiri show patient paroxysm nocturn
hemoglobinuria pnh effect safe switch treatment soliri everi week treatment
ultomiri everi week ultomiri safeti profil consist soliri total data
favor ultomiri soliri aim convert pnh patient soliri ultomiri end
also work phase clinic trial ultomiri ahu gmg diseas
current address alxn drug soliri
also market strensiq hypophosphatasia kanuma lyosom acid lipas defici
lal-d decemb three phase clinic program one phase ii program
impact major develop august patent trial appeal board ptab
announc would review claim relat three patent alxn key drug soliri request
neg outcom ptab review could expos soliri biosimilar competit
earlier expect
complet acquisit syntimmun inc clinical-stag biotechnolog compani
develop antibodi therapi target neonat fc receptor fcrn million
potenti addit milestone-depend payment million lead candid
acquisit monoclon antibodi inhibit interact fcrn
immunoglobulin igg igg immun complex studi phase trial
treatment igg-medi autoimmun diseas
may acquir wilson therapeut ab total consider million result
acquisit ad pipelin candid highli innov drug candid
current earli stage phase clinic trial treatment patient wilson
diseas pipelin
prior last major acquisit june acquir synageva biopharma
geva nr billion consist cash share
geva share geva kanuma treatment lysosom acid lipas defici orphan drug statu
us eu
financi trend alxn sale increas year-over-year billion billion
reflect five-year compound annual growth rate compound-annual-growth-rate compani ep expand
year-over-year reflect five-year compound-annual-growth-rate given compani low debt level
decemb posit free cash flow past five fiscal year think
well-posit continu fund research develop effort even extern
financ becom significantli limit decemb leverag ratio net debt
trailing-twelve-month ebitda annual million
independ chairman
board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc septemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
measur taken legisl regulatori
bodi lower drug price
democrat appear motiv
address drug price still think
suffici bipartisan impetu effect
signific chang near futur
anoth sourc price pressur drug
manufactur pharmaci benefit
manag pbm health insur
exert influenc drug
prescript price especi sinc
major pbm merg major insur
biolog price competit innov
act bpcia grant
exclus period brand biolog maker
fda-approv biosimilar
manufactur aggress use patent
law commerci leverag delay
commerci biosimilar
brand biolog maintain market
domin longer result bar
radic regulatori legisl chang
expect biosimilar continu advanc
slowli next sever year
year-to-d septemb
compar rise valu
 composit index
declin
posit outlook biotechnolog
histor defens sub-industri
expect see commerci
develop mani new innov therapi
declin preval patent
expir biotechnolog
compani trade discount
market think remedi
robust pipelin new drug brought
market fda approv novel drug increas
shatter
previou record sinc novel
approv set think mani
drug either newli approv
late-stag clinic trial consider
commerci prospect repres major
advanc therapi diseas
sclerosi cancer
pace deal slower
recent year mega-d
announc bristol-my
squibb acquisit celgen
celg acquisit
botox manufactur allergan matur
biopharmaceut firm look off-set
lost revenu expir patent fail
ventur promis late-stag pipelin
addit exampl think gilead
scienc could
interest larg collabor
agreement biotechnolog compani
low debt level attract valuat
rel industri make
think investor interest biotechnolog
stock mute recent high drug
price come heighten scrutini
 polit apparatu last
year despit talk lower drug
price seen particularli sever
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
higher estim due stronger-than-expect sale soliri
initi ep sale increas million soliri
sale grew million volum increas ultomiri
approv fda decemb complet
first month sale us januari alreadi convert
soliri paroxysm nocturn hemoglobinuria pnh patient ultomiri aim
convert pnh patient end aggress goal also
intend rapidli expand patient base given goal price
ultomiri favor patient also began proactiv offer discount
strensiq expect price headwind revenu
inc lift target
above-p ep estim ep
vs higher estim rais ep
lower ep sale
increas million soliri sale grew million
volum increas end septemb gener myasthenia
gravi gmg patient soliri therapi increas
number patient end june launch soliri gmg
turn success soliri launch expect
launch drive continu revenu growth think guidanc
increas quarter larg success gmg launch
also announc collabor discov
develop rnai therapi complement-medi diseas ad four rnai
candid pre-clin develop /kevin huang cfa
analyst research note compani news
pm et cfra maintain buy opinion share alexion
pharmaceut inc today announc intent
acquir achn initi net payment
approxim million conting valu right per share
fda approv drug danicopan per share phase
trial initi clinic candid assum
roadblock think certainli could especi around ftc
approv expect acquisit close think
deal make lot sens mitig potenti
competit achn work treat paroxysm nocturn hemoglobinuria
 pnh deal also complement core expertis achn
advanc candid danicopan phase studi pnh patient
sub-optimal respons soliri ultra-rar kidney diseas /kevin
et cfra keep buy opinion share
share trade sharpli today news patent
trial appeal board ptab review claim relat three patent
key drug soliri compris product revenu
previous highlight signific revenu concentr soliri
signific risk neg outcom ptab review could expos
soliri biosimilar competit howev
alreadi expect soliri sale could face competit pressur
view success execut strategi mitig
competit pressur strategi primarili involv convert soliri
patient newer conveni drug ultomiri expect
ptab review take year /kevin huang cfa
pm et cfra maintain buy opinion share
lower target base multipl
ep estim ep vs
exceed consensu estim rais ep
ep sale billion
reflect yoy growth driven increas volum off-set
foreign currenc headwind price headwind price headwind
larg relat on-going disput canadian drug price
board begin week paroxysm nocturn
hemoglobinuria pnh patient convert treatment soliri
ultomiri last quarter septemb expect
decis valid two patent relat soliri europ
even outcom neg biosimilar competit soliri least
three year away strategi make ultomiri standard care
pm et cfra reiter buy opinion share alexion
keep target base
multipl ep estim ep
vs significantli exceed consensu estim due
out-performance soliri sale rais ep
sale increas million driven sale soliri
gener myasthenia gravi gmg convers patient ultomiri
core busi growth soliri sale grew million volum
increas ultomiri achiev million sale first full
quarter commerci avail begin week
paroxysm nocturn hemoglobinuria pnh patient convert
treatment soliri ultomiri forecast remain track
convert pnh patient end next catalyst
fda decis soliri neuromyel optica spectrum disord nmosd
action date june /kevin huang cfa
pm et cfra maintain buy opinion share alexion
pharmaceut inc lift target
base in-lin peer multipl ep
estim rais today ep vs
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
